Safety and Immunogenicity of a Zoster Vaccine in SLE

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the safety and immunogenicity of a herpes zoster vaccine in patients with SLE.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™

NCT02958345

Herpes Zoster Fibrosis

COMPLETED PHASE4

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

NCT02723773

Herpes Zoster Herpes Zoster Vaccine

COMPLETED PHASE3

Immune Response to Varicella-Zoster Vaccination and Infection

NCT00921999

Chickenpox Herpes Zoster

COMPLETED

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

NCT02151110

Healthy Volunteer

COMPLETED PHASE1

A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT07205796

Herpes Zoster

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Herpes zoster (HZ) (Shingles) is a painful condition caused by reactivation of varicella zoster virus (VZV) that remains dormant after primary infection. HZ reactivation may cause significant morbidity such as post-herpetic neuralgia and even mortality for disseminated infection, particularly in immunocompromised individuals.

HZ vaccine (Zostavax) is essentially a larger-than-normal dose of the chickenpox vaccine, which contains the Oka strain of live attenuated VZV. Zostavax has been shown to be safe and protective in immunocompetent elderly populations (\>60 years of age) by reducing reactivation of HZ by 51% and post-herpetic neuralgia by 66%. Another study also demonstrated efficacy of Zostavax in reducing HZ infection by 70% in adults aged 50-59 years.

Data regarding the use of HZ vaccine in patients with rheumatic diseases are scant. A recent observational study involving 463,541 US patients with rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis and ankylosing spondylitis showed that 4% of patients had received HZ vaccination. After a median observation period of 2 years, the rate HZ reactivation among vaccinated patients was significantly lower than that of unvaccinated group (hazard ratio 0.61 \[0.52-0.71\]). Among 633 patients exposed to biologics at the time of vaccination, no cases of HZ or varicella infection occurred in the subsequent 42 days after vaccination. Thus, the vaccine appears to be safe in patients with autoimmune rheumatic diseases even receiving the biological agents.

HZ reactivation is fairly common in patients with systemic lupus erythematosus (SLE).

However, data regarding HZ vaccination in SLE patients are generally lacking. Safety and efficacy of HZ vaccination has recently been demonstrated in other immunocompromised groups such as HIV infection, post-chemotherapy and hematological malignancies. According to the 2011 EULAR recommendation, HZ vaccination may be considered in patients with autoimmune inflammatory rheumatic diseases provided that they are less seriously immunosuppressed.

The current study is designed to test for the immunogenicity and safety of a HZ vaccine (Zostavax) in patients with stable SLE who are receiving minimal immunosuppressive therapies for maintenance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SLE (vaccine)

Zostavax SC injection (0.65ml)

Group Type ACTIVE_COMPARATOR

Zostavax

Intervention Type BIOLOGICAL

Vaccination of a zoster vaccine (Zostavax)

SLE (placebo)

Placebo SC injection (normal saline 0.65ml)

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type BIOLOGICAL

placebo administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zostavax

Vaccination of a zoster vaccine (Zostavax)

Intervention Type BIOLOGICAL

placebo

placebo administration

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. SLE patients who fulfill ≥4 of the 1997 ACR (17) or the 2012 SLICC/ACR criteria for SLE (18)
2. Age ≥18 years
3. Clinically inactive disease with SELENA-SLEDAI score \<6 (see below) and receiving stable dose of immunosuppressive agents for ≥6 months
4. History of varicella (chickenpox) or herpes zoster infection in the past
5. Willing to comply with all study procedures

Exclusion Criteria

1. Active infection, including upper respiratory tract infection
2. Active untreated tuberculosis
3. Human immunodeficiency virus (HIV) infection
4. Lymphocyte count \<500/mm2
5. Reduced serum IgG, IgA or IgM level (below normal range)
6. Serum creatinine \>200umol/L
7. History of hematological malignancies (eg. lymphoma, leukaemia) and other solid tumors
8. Patients receiving doses of immunosuppressive agents exceeding the following:

* Prednisolone (\>15mg) or equivalent
* Azathioprine (\>100mg/day)
* Mycophenolate mofetil (\>1000mg/day)
* Cyclosporin A (\>100mg/day)
* Tacrolimus (\>3mg/day)
* Methotrextate (\>15mg/week)
* Cyclophosphamide (any dose)
* Biological agents eg. rituximab, belimumab (any dose)
9. Patients who are pregnant or plan to become pregnancy within one year of study entry
10. Patients who cannot give a written consent (mentally incapable or illiterate)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No